JP7381500B2 - 外傷性脳損傷を検出するための組成物および方法 - Google Patents

外傷性脳損傷を検出するための組成物および方法 Download PDF

Info

Publication number
JP7381500B2
JP7381500B2 JP2020567093A JP2020567093A JP7381500B2 JP 7381500 B2 JP7381500 B2 JP 7381500B2 JP 2020567093 A JP2020567093 A JP 2020567093A JP 2020567093 A JP2020567093 A JP 2020567093A JP 7381500 B2 JP7381500 B2 JP 7381500B2
Authority
JP
Japan
Prior art keywords
carbons
alkyl
heteroarylene
heterocycloalkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020567093A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525875A (ja
JP2021525875A5 (cg-RX-API-DMAC7.html
Inventor
ステラ サッラーフ,
リンジー エム. ランドルフ,
スハイル ラスール,
Original Assignee
アミディス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アミディス, インコーポレイテッド filed Critical アミディス, インコーポレイテッド
Publication of JP2021525875A publication Critical patent/JP2021525875A/ja
Publication of JP2021525875A5 publication Critical patent/JP2021525875A5/ja
Priority to JP2023188467A priority Critical patent/JP7583895B2/ja
Application granted granted Critical
Publication of JP7381500B2 publication Critical patent/JP7381500B2/ja
Priority to JP2024192794A priority patent/JP2025016675A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
    • A61B5/4064—Evaluating the brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Eye Examination Apparatus (AREA)
JP2020567093A 2018-05-31 2019-05-31 外傷性脳損傷を検出するための組成物および方法 Active JP7381500B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023188467A JP7583895B2 (ja) 2018-05-31 2023-11-02 外傷性脳損傷を検出するための組成物および方法
JP2024192794A JP2025016675A (ja) 2018-05-31 2024-11-01 外傷性脳損傷を検出するための組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862678900P 2018-05-31 2018-05-31
US62/678,900 2018-05-31
US201862733025P 2018-09-18 2018-09-18
US62/733,025 2018-09-18
PCT/US2019/034977 WO2019232422A1 (en) 2018-05-31 2019-05-31 Compositions and methods for detection of traumatic brain injury

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023188467A Division JP7583895B2 (ja) 2018-05-31 2023-11-02 外傷性脳損傷を検出するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2021525875A JP2021525875A (ja) 2021-09-27
JP2021525875A5 JP2021525875A5 (cg-RX-API-DMAC7.html) 2022-05-17
JP7381500B2 true JP7381500B2 (ja) 2023-11-15

Family

ID=68697319

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020567093A Active JP7381500B2 (ja) 2018-05-31 2019-05-31 外傷性脳損傷を検出するための組成物および方法
JP2023188467A Active JP7583895B2 (ja) 2018-05-31 2023-11-02 外傷性脳損傷を検出するための組成物および方法
JP2024192794A Pending JP2025016675A (ja) 2018-05-31 2024-11-01 外傷性脳損傷を検出するための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023188467A Active JP7583895B2 (ja) 2018-05-31 2023-11-02 外傷性脳損傷を検出するための組成物および方法
JP2024192794A Pending JP2025016675A (ja) 2018-05-31 2024-11-01 外傷性脳損傷を検出するための組成物および方法

Country Status (8)

Country Link
US (2) US12478693B2 (cg-RX-API-DMAC7.html)
EP (1) EP3803416A4 (cg-RX-API-DMAC7.html)
JP (3) JP7381500B2 (cg-RX-API-DMAC7.html)
CN (2) CN112424606B9 (cg-RX-API-DMAC7.html)
AU (1) AU2019279001B2 (cg-RX-API-DMAC7.html)
CA (1) CA3100700A1 (cg-RX-API-DMAC7.html)
MA (1) MA52796A (cg-RX-API-DMAC7.html)
WO (1) WO2019232422A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019372432B2 (en) * 2018-11-02 2025-05-29 Amydis, Inc. Phosphate compounds for detecting neurological disorders
JP7591040B2 (ja) * 2019-09-18 2024-11-27 アミディス, インコーポレイテッド リン酸化タウタンパク質への結合を介した神経障害を検出する方法
US20240325572A1 (en) * 2021-07-15 2024-10-03 Amydis, Inc. N-heterocyclyl substituted 2-cyano-3-(naphthalen-2-yl)acrylamide derivatives as fluorophors for detection of amyloid and amyloid-like proteins for diagnosis of neurodegenerative disorders
US20260217667A1 (en) * 2023-01-18 2026-07-30 Amydis, Inc. Amyloid targeting agents

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020036750A1 (en) 2000-09-23 2002-03-28 Eberl Heinrich A. System and method for recording the retinal reflex image
JP2012503012A (ja) 2008-09-18 2012-02-02 セダーズ−シナイ メディカル センター アルツハイマー病を検出するための光学的方法
US20120282169A1 (en) 2009-11-06 2012-11-08 Adlyfe, Inc. Detection and treatment of traumatic brain injury
JP2013513619A (ja) 2009-12-10 2013-04-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アミロイド結合剤
JP2013545516A (ja) 2010-10-25 2013-12-26 バードナー,スティーブン アルツハイマー病、外傷性脳損傷、黄斑変性症、複数の神経変性障害および眼疾患の診断、進行および病気経過予想における網膜内のアミロイドの検出装置および方法
WO2015188142A1 (en) 2014-06-05 2015-12-10 Cedars-Sinai Medical Center Diagnosis and monitoring of traumatic brain injury by imaging retinal abnormalities
WO2017004560A1 (en) 2015-07-02 2017-01-05 The Regents Of The University Of California Methods and compositions for amyloid aggregates
JP2017512834A (ja) 2014-03-19 2017-05-25 アミディス・ダイアグノスティックス・インコーポレイテッド アミロイド標的剤及びその使用方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5043013A (en) 1987-12-30 1991-08-27 Milliken Research Corporation Washable ink compositions
US5177064A (en) 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
US6541454B1 (en) 1995-04-04 2003-04-01 Yissum Research Development Company Of The Hebrew University Jerusalem Phosphonates, biphosphonates and pharmaceutical compositions containing them
US6048662A (en) 1998-12-15 2000-04-11 Bruhnke; John D. Antireflective coatings comprising poly(oxyalkylene) colorants
EP1431280A1 (en) 2001-08-29 2004-06-23 Kyowa Hakko Kogyo Co., Ltd Aryl sulfamate derivatives
WO2005040337A2 (en) 2003-05-20 2005-05-06 The Regents Of The University Of California METHODS FOR BINDING AGENTS TO β-AMYLOID PLAQUES
AU2005310979A1 (en) * 2004-11-16 2006-06-08 Bellus Health (International) Limited Compounds for the treatment of CNS and amyloid associated diseases
ATE525664T1 (de) 2004-11-22 2011-10-15 Abbott Medical Optics Inc Copolymerisierbare methin- und anthrachinon- verbindungen und artikel damit
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
JP2008013446A (ja) 2006-07-03 2008-01-24 Neugen Pharma:Kk 酸化ストレスによる細胞変性を分子背景とする難治性疾患の治療または予防剤
US20090191193A1 (en) 2006-08-02 2009-07-30 Temple University-Of The Commonwealth System Of Higher Education Aryl Vinyl Sulfides, Sulfones, Sulfoxides and Sulfonamides, Derivatives Thereof and Therapeutic Uses Thereof
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP3231804B1 (en) 2008-03-21 2021-03-03 The General Hospital Corporation Compounds and compositions for the detection and treatment of alzheimer's disease and related disorders
CN102115429B (zh) 2010-01-06 2013-02-27 中国科学院上海药物研究所 (e)-1-(3,5-二甲氧基苯基)-2-(3,5-二羟基-4-甲氧基苯基)乙烯及其制备方法和用途
KR101194337B1 (ko) 2010-07-14 2012-10-24 웅진코웨이주식회사 레티노이드 유도체 및 그를 포함하는 화장료 조성물
EP2605694B1 (en) 2010-08-16 2021-10-27 Cognoptix, Inc. Method for detecting amyloid proteins
CA2815960C (en) 2010-10-29 2019-01-22 Clino Ltd. Tau imaging probe
US9588129B2 (en) 2013-03-15 2017-03-07 Amira Medical Technologies Inc. Methods for analyzing blood to detect diseases associated with abnormal protein aggregation
EP3068388A4 (en) 2013-11-11 2017-04-12 Board of Regents of the University of Texas System Neuroprotective compounds and use thereof
EP3068283A1 (en) 2013-11-12 2016-09-21 Cognoptix, Inc. Method for measuring fluorescence in ocular tissue
US9605315B2 (en) * 2014-03-26 2017-03-28 The University Of Montana Detection of traumatic brain injury
EP3191107A2 (en) 2014-09-12 2017-07-19 Amydis Diagnostics, Inc. In vitro compositions comprising human sample and amyloid targeting agent
EP3702786A1 (en) * 2014-10-06 2020-09-02 Université de Genève Markers and their use in brain injury
GB201603967D0 (en) 2016-03-08 2016-04-20 Univ Birmingham Biomarkers of traumatic brain injury
JP7029718B2 (ja) 2017-07-31 2022-03-04 国立研究開発法人量子科学技術研究開発機構 リン酸化タウタンパク質の測定方法
AU2019372432B2 (en) 2018-11-02 2025-05-29 Amydis, Inc. Phosphate compounds for detecting neurological disorders
JP7591040B2 (ja) 2019-09-18 2024-11-27 アミディス, インコーポレイテッド リン酸化タウタンパク質への結合を介した神経障害を検出する方法
US20240165274A1 (en) 2021-03-12 2024-05-23 Amydis, Inc. Methods of detecting systemic amyloidosis via binding to misfolded or aggregated protein
US20240325572A1 (en) 2021-07-15 2024-10-03 Amydis, Inc. N-heterocyclyl substituted 2-cyano-3-(naphthalen-2-yl)acrylamide derivatives as fluorophors for detection of amyloid and amyloid-like proteins for diagnosis of neurodegenerative disorders
US20260217667A1 (en) 2023-01-18 2026-07-30 Amydis, Inc. Amyloid targeting agents

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020036750A1 (en) 2000-09-23 2002-03-28 Eberl Heinrich A. System and method for recording the retinal reflex image
JP2012503012A (ja) 2008-09-18 2012-02-02 セダーズ−シナイ メディカル センター アルツハイマー病を検出するための光学的方法
US20120282169A1 (en) 2009-11-06 2012-11-08 Adlyfe, Inc. Detection and treatment of traumatic brain injury
JP2013513619A (ja) 2009-12-10 2013-04-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アミロイド結合剤
JP2013545516A (ja) 2010-10-25 2013-12-26 バードナー,スティーブン アルツハイマー病、外傷性脳損傷、黄斑変性症、複数の神経変性障害および眼疾患の診断、進行および病気経過予想における網膜内のアミロイドの検出装置および方法
JP2017512834A (ja) 2014-03-19 2017-05-25 アミディス・ダイアグノスティックス・インコーポレイテッド アミロイド標的剤及びその使用方法
WO2015188142A1 (en) 2014-06-05 2015-12-10 Cedars-Sinai Medical Center Diagnosis and monitoring of traumatic brain injury by imaging retinal abnormalities
WO2017004560A1 (en) 2015-07-02 2017-01-05 The Regents Of The University Of California Methods and compositions for amyloid aggregates

Also Published As

Publication number Publication date
MA52796A (fr) 2021-04-14
AU2019279001B2 (en) 2025-11-27
JP7583895B2 (ja) 2024-11-14
CN112424606A (zh) 2021-02-26
EP3803416A4 (en) 2022-05-18
JP2024028695A (ja) 2024-03-05
JP2025016675A (ja) 2025-02-04
EP3803416A1 (en) 2021-04-14
US20260207789A1 (en) 2026-07-23
CN119985995A (zh) 2025-05-13
US20210369873A1 (en) 2021-12-02
JP2021525875A (ja) 2021-09-27
CN112424606B (zh) 2025-01-14
AU2019279001A1 (en) 2020-12-03
WO2019232422A1 (en) 2019-12-05
CN112424606B9 (zh) 2025-03-07
US12478693B2 (en) 2025-11-25
CA3100700A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
JP7583895B2 (ja) 外傷性脳損傷を検出するための組成物および方法
JP7664201B2 (ja) アミロイド標的剤及びその使用方法
JP7637288B2 (ja) 神経障害を検出するためのリン酸化合物
JP2024177285A (ja) リン酸化タウタンパク質への結合を介した神経障害を検出する方法
CN117916225A (zh) N-杂环基取代的2-氰基-3-(萘-2-基)丙烯酰胺衍生物作为荧光团用于检测类淀粉蛋白和类淀粉样蛋白以诊断神经退行性病症
JP2013508384A (ja) アルファアドレナリン受容体モジュレーター
CN116327950A (zh) 组合物用于治疗神经退行性疾病的神经精神症状的用途
US20260092037A1 (en) Crystalline salt forms of n-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl) methyl)-3-chloro-5-fluorobenzamide and methods of use thereof
JP2026514651A (ja) Nr2b選択的nmda受容体拮抗薬としてのベンジリデンアミノグアニジン誘導体とその治療への応用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220509

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230724

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231004

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231102

R150 Certificate of patent or registration of utility model

Ref document number: 7381500

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150